Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation.

ABSTRACT: Elderly non-small cell lung cancer (NSCLC) patients do not always benefit from standard treatments due to impaired organ function and/or multiple comorbidities. Our study aimed to determine the efficacy and safety of aumolertinib as a first-line therapy in NSCLC patients aged ≥65 and <65 years in clinical practice.We enrolled 100 patients with stage IIA-IVB epidermal growth factor receptor-mutant NSCLC who received aumolertinib alone as the first-line therapy. Efficacy and safety were compared between patients aged ≥65 and <65 years in different subgroups. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.Overall, ORR and DCR were 76% and 98%, respective

SUBMITTER: Liu N 

PROVIDER: S-EPMC12599707 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature